通过向FOXO1/HMOX1轴,Vorapaxar增强了与线粒体相关的铁死,为癌症免疫疗法提供了基础
Qian Zhou1, Yuming Sun2, Songtao Du3
1Department of Dermatology, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan Province, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, 87 Xiangya Road, Changsha 410008, Hunan Province, China; Furong Laboratory, 87 Xiangya Road, Changsha 410008, Hunan Province, China; Hunan Key Laboratory of Skin Cancer and Psoriasis, Hunan Engineering Research Center of Skin Health and Disease, Xiangya Hospital, Central South University, 87 Xiangya Road, Changsha 410008, Hunan Province, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, 87 Xiangya Road, Changsha 410008, Hunan Province, China.
一种抗血小板药物Vorapaxar促进细胞死亡的一种形式ferroptosis,以增强癌症免疫疗法. 这种双重行动策略可能会改善癌症患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 癌症免疫疗法在治疗方面取得了进步,但面临着抗药性和血栓栓塞等挑战.
- 向铁亡是一种提高免疫疗法疗效的潜在策略.
- 需要双重目的的策略来解决癌症进展和与治疗相关的风险.
研究的目的:
- 识别促进铁亡并减轻血栓栓塞风险的抗血小板药物.
- 研究vorapaxar在诱导铁亡和增强抗瘤免疫力的机制.
- 评估与铁死相关的生物标志物在免疫疗法反应中的临床相关性.
主要方法:
- 对20种FDA批准的抗血小板药物的系统查.
- 涉及分叉盒O1 (FOXO1) 和血红氧酶1 (HMOX1) 途径的机制研究.
- 在体内实验中使用了各种黑色素瘤模型 (B16F10,Braf/Pten驱动,PBMC人性化小鼠).
- 对FOXO1/HMOX1联合表达与免疫治疗反应的临床相关性分析.
主要成果:
- 沃拉帕沙尔被确定为一种强大的亲铁菌剂.
- 沃拉帕沙尔抑制FOXO1酸化,促进核转位和上调HMOX1,导致铁亡.
- 在临床前黑色素瘤模型中,Vorapaxar增强了免疫疗法诱导的瘤铁和抗瘤免疫力.
- 高FOXO1/HMOX1联合表达与更好的免疫疗法反应和无进展生存相关.
结论:
- 沃拉帕沙尔通过诱导铁亡并可能减少血栓栓塞事件来表现出双重功能.
- 沃拉帕沙尔作为癌症免疫治疗的有希望的辅助剂,增强了它的疗效.
- 临床数据表明,FOXO1/HMOX1通路的激活与接受免疫治疗的患者的改善结果有关.
相关概念视频
Targeted Cancer Therapies
There are several types of targeted therapies against...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Immunotherapy

